Sinopharm CNBG Announces Pneumonia-Specific COVID-19 Drug

BEIJING--September 20, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Sinopharm China National Biotec Group (Sinopharm CNBG) recently announced the intravenous COVID-19 Human Immunoglobulin (pH4), which was developed by its subsidiary Tiantan Biological Company Limited, was approved for clinical trials by the Chinese National Medical Products Administration (NMPA).